Proinsulin II-specific T-cell receptor (Proinsulin-specific TCR)

Proinsulin II-specific T-cell receptors (TCRs) are specialized proteins on the surface of autoreactive T lymphocytes that recognize proinsulin-derived peptides, serving as a primary driver of pancreatic beta-cell destruction in Type 1 Diabetes (T1D). In the NOD mouse model, Proinsulin II (encoded by the Ins2 gene) is the dominant autoantigen, and TCRs specific for its B:9-23 epitope are essential for the initiation of the disease (Nakayama et al., Nature, 2005). In humans, T cells expressing TCRs specific for proinsulin peptides are found in the pancreatic islets and peripheral blood of patients, where they contribute to the loss of insulin-producing cells (Pathiraja et al., Diabetes, 2015). These TCRs bind to peptide-MHC complexes, such as HLA-DQ8 or HLA-DR4 in humans, leading to T-cell activation and inflammatory damage. Therapeutic strategies targeting these TCRs include antigen-specific immunotherapies (ASIs) like peptide vaccines (e.g., C19-A3) and DNA vaccines (e.g., BHT-3021), which aim to induce immune tolerance or regulatory T-cell responses (Roep et al., Journal of Autoimmunity, 2010). The goal of these interventions is to selectively silence the pathogenic autoimmune response while maintaining overall immune competence (Gottlieb et al., Clinical Immunology, 2013).

Other names

Insulin-specific T-cell receptorProinsulin-reactive TCRAutoreactive T-cell receptorIns2-specific TCR

Induction of antigen-specific immune tolerance, anergy, or clonal deletion of autoreactive T cells to prevent beta-cell destruction.